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Abstract. In breast cancers, the large conductance Ca2+ and
voltage sensitive K+ (BKCa) channels have been hypothesized
to function as oncoproteins, yet it remains unclear how inhibition of channel activity impacts oncogenesis. We demonstrated
herein that iberiotoxin (IbTX), an inhibitor of BKCa channels,
differentially modulated the in vitro tumorigenic activities
of hormone-independent breast cancer cells. Specifically, in
HER-2/neu-overexpressing UACC893 cells and triple‑negative
MDA-MB-231 cells, IbTX selectively attenuated anchorageindependent growth with concomitant downregulation
of β -catenin as well as total and phosphorylated Akt and
HER-2/neu. By contrast, HER-2/neu-overexpressing SK-BR-3
cells were insensitive to IbTX. Molecular analyses showed an
absence of β -catenin and a dose-dependent upregulation of
total and phosphorylated Akt and HER-2/neu in these cells.
Taken together, these studies identify β-catenin as a putative
modulator of the inhibitory actions of IbTX in sensitive breast
cancer cells.

tion, alternative splicing or increased protein half-life (5-8). In
addition, neoplastic BKCa channels may possess augmented
sensitivity to Ca2+ and voltage and hence generate K+ currents
in environments where their normal counterparts are silent (5).
The enhanced activity of BKCa channels shifts cellular transmembrane potential to favor proliferative phenotypes (9).
It is therefore plausible for BKCa channels to be considered
putative targets for anticancer therapies. The contributions
of BKCa channels to cancer cell migration and invasion have
been previously demonstrated; however, their role in tumorigenesis has not been investigated (1,3,10).
The present study presents novel findings that an inhibitor
of BKCa channels, iberiotoxin (IbTX), selectively decreased
anchorage-independent growth and tumorigenicity in breast
cancer cells expressing β-catenin. Our data suggest that the
attenuated tumorigenicity is a result of depolarizing shifts in
cell transmembrane potential and subsequent downregulation
of β-catenin and (phospho)Akt and HER-2/neu protein levels.

Introduction

Materials and methods

The large conductance calcium and voltage activated potassium
(BKCa) channels have been shown to function as oncogenes in
certain cancers (1-4). BKCa channels generate vast amounts
of outward K+ currents and therefore are powerful modulators
of the transmembrane potential of a cell. BKCa channels are
overexpressed in many types of cancers via gene amplifica-

Cell culture. UACC893, MDA-MB-231, SK-BR-3 and
MCF10A cells were purchased from ATCC (Manassas, VA,
USA). Cells were propagated in DMEM:F12 medium (SigmaAldrich, St. Louis, MO, USA) supplemented with 20% fetal
bovine serum (FBS).
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Membrane potential assays. Cells were pre-loaded for 30 min
with 2 µmol/l of a membrane potential-sensitive dye DiBAC4(3)
(Invitrogen, Life Technologies, Carlsbad, CA, USA) in buffer
containing (mmol/l): 20 HEPES, 140 NaCl, 2 KCl, 1 MgCl2,
2 CaCl 2, 10 glucose prior to seeding onto mouse laminin
(Sigma-Aldrich)-coated glass bottom 35-mm tissue culture
dishes (MatTek Corporation, Ashland, MA, USA). After 24 h,
dishes were placed on a microscope stage pre-heated to 37˚C,
and 10 nmol/l IbTX (Sigma-Aldrich) was added. Immediately
following IbTX, cells were observed every minute for 20 min
using the 488 nm laser of an LSM 510 Zeiss confocal scanning
microscope (Zeiss, Jena, Germany). Signals from 5 to 7 regions
of interest were quantified and averaged using LSM 510 image
browser (Zeiss). Data were fitted using non-linear regression
analysis and significant differences estimated by ANOVA
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and post hoc Bonferroni's t-test (SigmaPlot; Systat Software,
Inc., San Jose, CA, USA). A P-value ≤0.05 was considered to
indicate a statistically significant result.
Cell viability assays. Cells were seeded into 6-well cluster
dishes at 100,000 cells/well in DMEM:F12 supplemented
with 20% FBS in the absence or presence of IbTX (2, 5, 10,
25 and 50 nmol/l) for 48 h. Subsequently, cells were stained
with trypan blue and counted using Countess Automated Cell
Counter (Invitrogen). Experiments were repeated three times,
and statistical differences were assessed using the Student's
t-test.
Soft agar assays. Soft agar assays were performed as previously described (17). Briefly, following IbTX incubations as
described for cell viability assays, cells were re-suspended
in 0.3% agar in DMEM:F12 tissue culture medium supplemented with 20% FBS. Cell suspensions were seeded onto
0.5% basal agar in 6-well cluster dishes at 1,000 cells/well.
The cell colonies were visualized 21 days later using crystal
violet solution (crystal violet 0.005% and citric acid 0.1%) and
manually counted. Experiments were repeated at least twice
in quadruplicate.
Western immunoblotting. Whole cell lysates were isolated using
RIPA buffer containing (mmol/l) 150 NaCl, 50 Tris pH 7.4,
1 EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS
and protease and phosphatase inhibitors. Twenty micrograms
of protein was separated on 4-20% Tris-HCl gels (Bio-Rad,
Hercules, CA, USA), transferred on nitrocellulose membranes,
and blocked in 5% BSA for 1 h at room temperature. Blots
were then incubated with the rabbit anti-HER-2/neu antibody
(1:500 EMD; Millipore, Billerica, MA, USA), rabbit β-catenin
antibody (1:500), rabbit T308 phospho-Akt or total Akt antibody (both from Cell Signaling Technology, Danvers, MA,
USA) overnight at 4˚C. Signals were detected with IRDye 680
secondary antibodies (1:5,000) for 1 h at room temperature
and visualized using LI-COR Odyssey Imaging System (both
from LI-COR, Lincoln, NE, USA). Blots were subsequently
incubated with mouse GAPDH antibody (1:1,000; Sigma)
and anti-mouse IRDye 800CW secondary antibody (1:5,000;
LI-COR) to ensure equal protein loading. N=3.
RNA isolation and qPCR. Total mRNA was isolated using the
mirVana miRNA isolation kit (Ambion, Life Technologies,
Carlbad, CA, USA). Following isolation, the NanoDrop M-1000
was used to determine the concentration and the quality of
the total RNA. A reverse transcription was performed using
the SuperScript III First-Strand Synthesis kit (Invitrogen, Life
Technologies) with 700 ng of total RNA. The gene expression
was then determined with a SYBR-Green PCR assay (Applied
Biosystems, Life Technologies, Carlbad, CA, USA) and run on
the Applied Biosystems Model 7900 Genetic Analyzer. The
data were normalized to the endogenous control 18s rRNA
and analyzed using the program SDS 2.1 (Applied Biosystems,
Life Technologies). Comparison of gene expression between
the breast cancer MDA-MB-231, SK-BR-3 and UACC893 cells
and the normal mammary MCF10A cells were completed
using the ΔΔCt method. Primer sequences are available upon
request.

Fluorescent immunocytochemistry. Cells seeded onto mouse
laminin-coated glass bottom 35-mm tissue culture dishes
for 24 h were fixed in 2% paraformaldehyde for 30 min and
permeabilized in 0.1% Triton X-100 for 4 min. Cells were
blocked in phosphate-buffered saline (PBS) supplemented
with 5% FBS + 1% NDS for 30 min at 37˚C and incubated with
the rabbit anti-BKCa antibody (Cell Signaling Technology)
diluted 1:500 in 0.1% blocking buffer for 30 min at 37˚C. The
signal was detected using the donkey anti-rabbit DyLight 488
antibody (Jackson ImmunoResearch, West Grove, PA, USA)
1:1,000 in 0.1% blocking buffer for 15 min at 37˚C. Cell nuclei
were counterstained with propidium iodide (5 mg/ml 1:10,000)
in PBS for 5 min at room temperature. Cells were visualized
with a Zeiss 510 laser confocal microscope, and images were
reconstructed using LSM Image Browser (both from Jena,
Germany).
Results
BKCa channels contribute to resting transmembrane potential. We began by using RT-PCR assays to establish the levels
of BKCa channel mRNA in several types of malignant and
non-malignant cell lines. We detected elevated levels of BKCa
channel mRNA in breast cancer cell lines (UACC893, SK-BR-3
and MDA-MB-231) compared to these levels in the nonneoplastic MCF10A cells (Fig. 1A). BKCa channel proteins,
detected using fluorescent immunocytochemistry, formed
typical clusters on plasma membranes in all breast cancer
cell models (Fig. 1B). Observations of live cells loaded with
a membrane potential sensitive dye revealed that the selective
BKCa channel inhibitor IbTX elicited cellular depolarization indicative of a presence of functional channels. Indeed,
IbTX depolarized cells in all three models albeit to a different
magnitude (Fig. 1C). The UACC893 cells were significantly
depolarized within 4 min after IbTX addition, after which
depolarization plateaued for the duration of the experiment.
The MDA-MB-231 cells did not acquire a plateau phase
but rather steadily increased their transmembrane potential
throughout the 20-min observation period. SK-BR-3 cells were
depolarized only transiently. The emergence of depolarizing
phases, despite differences in duration, suggests that the BKCa
channels regulate the resting transmembrane potential of all
three breast cancer cell lines examined.
BKCa channel inhibition selectively modulates anchorageindependent growth. Given that BKCa channels were
expressed and functional in our cancer cell lines, we asked
whether pharmacological inhibition of these channels could
lessen malignant phenotypes by impacting the ability of
cells to proliferate, survive and/or form tumors in vitro. We
found IbTX to attenuate de novo cell colony development in
the UACC893 cells (Fig. 2A, left upper panel) with minimal
inhibitory effects on anchorage-dependent cell proliferation
(Fig. 2A, right upper panel). A similar dynamic was observed
in the MDA-MB-231 cells where clonogenic growth (Fig. 2B,
left middle panel) but not anchorage-dependent proliferation
(Fig. 2B, right middle panel) was inhibited by IbTX. On the
contrary, IbTX was ineffective in modulating colony formation
(Fig. 2C, left lower panel) or proliferation (Fig. 2C, right lower
panel) of SK-BR-3 cells. Thus, IbTX appeared to specifically
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Figure 1. BKCa channels regulate the transmembrane potential in breast cancer cells. (A) Breast cancer cells displayed higher levels of BKCa transcripts
compared to benign mammary epithelial cells. Total RNA from MCF10A benign mammary epithelial cells and UACC893, MDA-MB-231 and SK-BR-3
beast cancer cells was assayed for BKCa transcript levels using quantitative RT-PCR. Statistically significant differences vs. the MCF10A cells. N=3, P≤0.05.
(B) BKCa channel proteins (green) were detected in UACC893 (upper panels), MDA-MB-231 (middle panels) and SK-BR-3 (lower panels) cells using fluorescent immunocytochemistry. Nuclei were counterstained with propidium iodide (red) and the image series were acquired using Zeiss 510 laser confocal
microscope. A series was reconstructed to generate three dimensional images rotated to present the lateral sides of the cells with apical surfaces facing atop of
their respective image. MDA-MB-231 cells did not possess basal-apical differentiation and appear flat in the images. Experiments were repeated at least three
times for each cell line. (C) IbTX differentially modulates transmembrane potential. UACC893 (upper panel), MDA-MB‑231 (middle panel) and SK-BR-3
(lower panel) cells pre-loaded with 2 µmol/l DiBac4(3) in membrane potential buffer and supplemented with 10 nmol/l IbTX were observed using a Zeiss 510
laser confocal microscope for 20 min with images captured every minute. Average signal intensities from 5 to 7 regions of interest were calculated and plotted.
Increased signal intensity signifies depolarization due to IbTX inhibition of BKCa channels by IbTX. Significant differences vs. start of experiment (1 min).
N=3. IbTX, iberiotoxin.

reduce the tumorigenic features of the neoplastic phenotype in
selected breast cancer models.

BKCa channel inhibition modulates oncogenic pathways. Both
UACC893 and SK-BR-3 cells express the HER-2/neu gene.
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Figure 2. IbTX selectively modulates anchorage-independent clonogenic growth. Cells were incubated with increasing concentrations of IbTX for 48 h, stained
with trypan blue and counted. Cells subsequently were seeded in agar-supplemented tissue culture media. Cell colonies were visualized with crystal violet
staining and counted. (A) In UACC893 cells, IbTX inhibited anchorage-independent colony growth in soft agar (left panel). Significant attenuation of anchoragedependent cell proliferation was observed only at 50 nmol/l (right panel). (B) IbTX suppressed clonogenic growth of MDA-MB-231 cells (left panel) without
exhibiting inhibitory effects on cell proliferation (right panel). (C) IbTX did not modulate anchorage-dependent (left panel) or anchorage-independent (right
panel) growth of SK-BR-3 cells. All assays were repeated at least twice in quadruplicate. Significant differences vs. IbTX-free controls (x-axis, 0). IbTX,
iberiotoxin.

Thus, it was possible that disparate trends in their tumorigenic
potential following IbTX treatment may have resulted from
IbTX-induced modulations of oncoprotein levels. HER-2/neu
levels decreased in the UACC893 cells at growth-inhibiting
IbTX concentrations (Fig. 3A). By contrast, SK-BR-3 cells,
which express both the long and short isoforms of HER-2/neu,
demonstrated increased HER-2 levels after IbTX addition
(Fig. 3A) (11). However, changes in HER-2/neu oncoprotein
expression cannot account for the attenuated tumorigenic
ability of triple-negative MDA-MB-231 cells, thus suggesting
alternative mechanisms of growth regulation.
Upon further investigation, we found that cells with reduced
tumorigenicity expressed β-catenin (Fig. 3B, UACC893 and
MDA-MB-231). IbTX-resistant SK-BR-3 cells were β-cateninnegative (data not shown); these findings are consistent with
earlier reports (12). In UACC893 and MDA-MB-231 cells,
both long and truncated isoforms of β -catenin were identified (Fig. 3B, β -catenin and tr β -catenin), although IbTX
decreased expression of only the long isoform (90 kDa) (13).
The protein kinase Akt is known to phosphorylate β-catenin
and regulate its activity (14). We therefore examined Akt levels
in UACC893 and MDA-MB-231 cells treated with IbTX. In

the UACC893 cells, T308 phospho-Akt was diminished with
increasing concentrations of IbTX; in MDA-MB-231 cells
both total and phospho-Akt were downregulated, concordant
with β-catenin levels. In contrast, SK-BR-3 cells demonstrated
fluctuating levels of phospho- and total-Akt that increased
at higher IbTX concentrations (Fig. 3C). Hence, β -catenindependent pathway(s) may mediate the inhibitory actions of
IbTX with regard to clonogenic potential in breast cancer cells.
Discussion
BKCa channels have previously been proposed as targets for
anticancer therapies in brain and prostate cancers due to their
presumptive pro-oncogenic roles. However, their contributions
to the pathogenesis of hormone-independent breast cancers
are not well understood (1). The present study implies that
BKCa channels may exert either pro- or anti-growth effects,
depending on the particular molecular composition of the
cancer cell type in question.
The growth-modulating roles of BKCa channels became
apparent in our experiments when we explored anchorageindependent cell growth. These findings are in accord with
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Figure 3. IbTX differentially regulates oncogenic pathways. (A) IbTX
attenuated the HER-2/neu levels in the UACC893 cells (HER-2/neu,
UACC893). SK-BR-3 cells express full length (HER-2/neu, SK-BR-3) and
truncated (p95 HER-2/neu, SK-BR-3) oncoprotein isoforms with both being
increased by IbTX. (B) IbTX downregulated the full length ( β -catenin)
but not truncated (trβ ‑catenin) β -catenin isoforms in the UACC893 and
MDA-MB-231 cells. (C) In the UACC893 cells, IbTX attenuated phosphorylated (T308pAkt, UACC893) but not total Akt (Akt, UACC893). Both
phosphorylated (T308pAkt, MDA‑MB‑231) and total (Akt, MDA-MB-231)
Akt were decreased in the MDA‑MB-231 cells with IbTX. In SK-BR-3 cells,
phosphorylated (T308pAkt, SK-BR-3) and total (Akt, SK-BR-3) Akt increased
at high IbTX concentrations. (D) GAPDH was used in the UACC893, MDAMB-231 and SK-BR-3 cell immunoblotting to ensure equal protein loading.
IbTX, iberiotoxin.

earlier reports that found the BKCa channels modulated the
tumorigenic potential of subpopulations of cancer cells (15).
Molecular studies provided insights into the mechanisms used
by BKCa channels to differentially regulate the tumorigenic
properties of breast cancer cells. IbTX is a potent and selective BKCa channel inhibitor with minimal off-target effects
at concentrations within the inhibitor's selectivity range (16).
In addition, cells with reduced tumorigenicity, i.e. UACC893
and MDA-MB-231, uniformly developed sustained transmembrane depolarization when IbTX was present. It is therefore
plausible that suppression of oncogene(s) levels, and hence
tumor formation, are secondary events occurring subsequent
to sustained increases in transmembrane potential.
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Notably, we also observed that BKCa channel downregulation via siRNAs did not recapitulate the inhibitory actions
of IbTX on in vitro tumorigenesis despite satisfactory transfection levels (data not shown). These findings lend further
credence to the importance of transmembrane potential for
tumorigenesis as siRNAs are far less efficient in inhibiting K+
currents compared to IbTX (17). TEA, a non-selective blocker
of K+ channels and depolarizing agent, has been shown to
hamper in vitro endometrial tumorigenesis akin to IbTX in
breast cancer models (18). A single discrepancy, namely the
enhanced tumorigenic activity upon TEA washout that did not
occur with IbTX, was due to the lower dissociation constant of
IbTX compared to TEA, thus ensuring IbTX retention in soft
agar (18). Hence, inhibitors with dissimilar chemical and pharmacological profiles that share similar depolarizing actions
can equivalently modulate anchorage-independent growth
in disparate cancer models, suggesting that transmembrane
potential mediates their inhibitory effects.
In the present study, tumor cell lines that showed
suppressed in vitro colony growth in the presence of IbTX
shared positivity for β -catenin. Thus, it is possible that a
canonical Wnt pathway could mediate the anti-tumorigenic
actions of IbTX. BKCa/β ‑catenin complexes have been
reported in cells of neural origin and in overexpression
systems where β-catenin determines BKCa channel surface
expression and clustering (19). However, in our experiments,
IbTX downregulated β -catenin levels without significantly
affecting the expression patterns of the BKCa channels. The
observed differences were not due to the presence of BKCa
splice variants with alterations in the β-catenin binding S10
domain (19). Moreover, β -catenin‑negative SK-BR-3 cells
not only have BKCa channels present on the cell surface, but
also respond to IbTX with β -catenin-independent increases
in the expression of BKCa channels. These findings imply
that breast cancer cells and neural cells/heterologous systems
utilize disparate mechanisms to sustain BKCa channel expression. Canonical Wnt signaling may be a prerequisite for the
antitumor effects of BKCa channel inhibitors; however, mechanisms other than BKCa/Wnt interactions may also mediate
these effects. Similarly, differential regulation of HER-2/
neu oncoprotein levels by IbTX cannot be ascribed solely to
previously reported HER-2neu/β-catenin complexes at least in
SK-BR-3 cells (20).
In conclusion, the present study suggests that: i) BKCa channels function as oncogenes in β-catenin-positive breast cancer
cells; ii) they direct their oncogenic input towards sustaining
the tumorigenic ability of cancer cells; and iii) inhibitors of
BKCa channels may modulate in vitro tumorigenesis via transmembrane depolarization.
Acknowledgements
This study was supported in part by the Biological Sciences
Funding Program of the Office of Vice-President for Research
of the University of Iowa, NIH R01CA99908 (K.K.L.) and NIH
R01-CA133114 (N.A.B.), and the Department of Obstetrics and
Gynecology Research Development Fund (K.K.L.). We thank
Kristina W. Thiel for assistance in the manuscript preparation.
V.P.K. is founder and CEO of HiBiotechnology, L.L.C. K.K.L.
is a co-founder of Immortagen, L.L.C.

538

SCHICKLING et al: BKCa channel inhibitor and breast cancer cells

References
1. Khaitan D, Sankpal UT, Weksler B, Meister EA, Romero IA,
Couraud PO and Ningaraj NS: Role of KCNMA1 gene in breast
cancer invasion and metastasis to brain. BMC Cancer 9: 258,
2009.
2. Tajima N, Itokazu Y, Korpi ER, Somerharju P and Käkelä R:
Activity of BKCa channel is modulated by membrane cholesterol
content and association with Na+/K+-ATPase in human melanoma
IGR39 cells. J Biol Chem 286: 5624-5638, 2011.
3. Mazar J, DeYoung K, Khaitan D, Meister E, Almodovar A,
Goydos J, Ray A and Perera RJ: The regulation of miRNA-211
expression and its role in melanoma cell invasiveness. PLoS
One 5: e13779, 2010.
4. Bloch M, Ousingsawat J, Simon R, Schraml P, Gasser TC,
Mihatsch MJ, Kunzelmann K and Bubendorf L: KCNMA1
gene amplification promotes tumor cell proliferation in human
prostate cancer. Oncogene 26: 2525-2534, 2007.
5. Liu X, Chang Y, Reinhart PH, Sontheimer H and Chang Y:
Cloning and characterization of glioma BK, a novel BK channel
isoform highly expressed in human glioma cells. J Neurosci 22:
1840-1849, 2002.
6. Lu R, Alioua A, Kumar Y, Eghbali M, Stefani E and Toro L:
MaxiK channel partners: physiological impact. J Physiol 570:
65-72, 2006.
7. Tian L, McClafferty H, Chen L and Shipston MJ: Reversible
tyrosine protein phosphorylation regulates large conductance
voltage- and calcium-activated potassium channels via cortactin.
J Biol Chem 283: 3067-3076, 2008.
8. So EC, Wu KC, Liang CH, Chen JY and Wu SN: Evidence
for activation of BKCa channels by a known inhibitor of focal
adhesion kinase, PF573228. Life Sci 89: 691-701, 2011.
9. Sundelacruz S, Levin M and Kaplan DL: Role of membrane
potential in the regulation of cell proliferation and differentiation.
Stem Cell Rev 5: 231-246, 2009.
10. Wondergem R and Bartley JW: Menthol increases human
glioblastoma intracellular Ca 2+, BK channel activity and cell
migration. J Biomed Sci 16: 90, 2009.

11. Arribas J, Baselga J, Pedersen K and Parra-Palau JL: p95HER2
and breast cancer. Cancer Res 71: 1515-1519, 2011.
12. He B, You L, Uematsu K, Xu Z, Lee AY, Matsangou M,
McCormick F and Jablons DM: A monoclonal antibody against
Wnt-1 induces apoptosis in human cancer cells. Neoplasia 6:
7-14, 2004.
13. Miyoshi K and Hennighausen L: β-Catenin: a transforming actor
on many stages Breast Cancer Res 5: 63-68, 2003.
14. Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H,
Mills GB, Kobayashi R, Hunter T and Lu Z: Phosphorylation of
β-catenin by AKT promotes β-catenin transcriptional activity. J
Biol Chem 282: 11221-11229, 2007.
15. Park JH, Park SJ, Chung MK, Jung KH, Choi MR, Kim Y, Chai YG,
Kim SJ and Park KS: High expression of large‑conductance Ca2+activated K+ channel in the CD133+ subpopulation of SH-SY5Y
neuroblastoma cells. Biochem Biophys Res Commun 396:
637-642, 2010.
16. Candia S, Garcia ML and Latorre R: Mode of action of
iberiotoxin, a potent blocker of the large conductance Ca(2+)activated K+ channel. Biophys J 63: 583-590, 1992.
17. Shimazu K, Takeda K, Yu ZX, Jiang H, Liu XW, Nelson PG
and Guroff G: Multiple acute effects on the membrane potential
of PC12 cells produced by nerve growth factor (NGF). J Cell
Physiol 203: 501-509, 2005.
18. Schickling BM, Aykin-Burns N, Leslie KK, Spitz DR and
Korovkina VP: An inhibitor of K+ channels modulates human
endometrial tumor-initiating cells. Cancer Cell Int 11: 25, 2011.
19. Bian S, Bai JP, Chapin H, Le Moellic C, Dong H, Caplan M,
Sigworth FJ and Navaratnam DS: Interactions between β-catenin
and the HSlo potassium channel regulates HSlo surface
expression. PLoS One 6: e28264, 2011.
20. Schroeder JA, Adriance MC, McConnell EJ, Thompson MC,
Pockaj B and Gendler SJ: ErbB- β -catenin complexes are
associated with human infiltrating ductal breast and murine
mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu
transgenic carcinomas. J Biol Chem 77: 22692-22698, 2002.

